You are here: Industry Insights > ulcerative colitis

News List

Bristol Myers Squibb presents data from True North trial of Zeposia (ozanimod) for ulcerative colitis expresspharma
October 12, 2020
Both primary and all key secondary efficacy endpoints showed statistically significant improvements with oral Zeposia versus placebo at Week 10 and Week 52.
Arena Announces First Subject Dosed Etrasimod Trial for Ulcerative Colitis americanpharmaceuticalreview
September 23, 2020
Arena Pharmaceuticals announced the first subject has been dosed in the ELEVATE UC 12 global Phase 3 trial evaluating etrasimod, an investigational, next-generation, once-daily, oral, selective sphingosine 1-phosphate (S1P) receptor modulator ...
Roche post mixed results for etrolizumab in ulcerative colitis pharmatimes
August 11, 2020
Roche’s investigational medicine etrolizumab has demonstrated mixed results in phase III studies in patients with moderately to severely active ulcerative colitis.
Final NICE green light for Janssen's Stelara in UC pharmatimes
June 18, 2020
The National Institute for Health and Care Excellence (NICE) has now issued a final green light for NHS use of Janssen's Stelara (ustekinumab) to treat ulcerative colitis.
Gilead and Galapagos announce positive topline results of phase 2b/3 trial of filgotinib in moderate pharmaceutical-business-review
May 27, 2020
Gilead Sciences and Galapagos announced positive topline results from SELECTION, a randomized, double-blind, placebo-controlled, Phase 2b/3 trial evaluating the efficacy and safety of the investigational, oral, once-daily ...
Lupin launches authorised generic version of Apriso expresspharma
May 19, 2020
Mesalamine Extended-Release Capsules 0.375 g (the authorized generic version) are indicated for the maintenance of remission of ulcerative colitis in patients 18 years of age and older.
AstraZeneca Recovers Global Rights to brazikumab from Allergan americanpharmaceuticalreview
May 14, 2020
AstraZeneca has completed a previously communicated agreement to recover the global rights to brazikumab (formerly MEDI2070), a monoclonal antibody targeting IL23, from Allergan.
EC approves subcutaneous formulation of Entyvio as maintenance therapy in ulcerative colitis or Croh pharmaceutical-business-review
May 13, 2020
Takeda Pharmaceutical announced that the European Commission has granted a Marketing Authorization for the subcutaneous (SC) formulation of Entyvio (vedolizumab).
SMC accepts Janssen’s ulcerative colitis drug Stelara for NHS use pharmaceutical-technology
April 17, 2020
Scottish Medicines Consortium (SMC) has accepted Janssen Pharmaceutical’s Stelara (ustekinumab) for use on the National Health Service (NHS) Scotland to treat moderately to severely active ulcerative colitis (UC) in adults.
Colorectal Cancer Risk Still Up in Patients With Ulcerative Colitis drugs
January 19, 2020
Patients with ulcerative colitis have an increased risk for colorectal cancer and colorectal cancer mortality, according to a study published in the January issue of The Lancet.

Previous page 1 2 3 4 5 Next page